Navigation Links
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Date:3/11/2008

it to home in on these cells, delivering its radioactive "payload" directly to the center of the tumor mass and thereby destroying it "from the inside out" with minimal radiation exposure to healthy tissue. Cotara is delivered using convection-enhanced delivery (CED), which targets the specific tumor site in the brain. In a previous clinical study, a subset of patients with recurrent glioblastoma treated with Cotara achieved a median survival of 38 weeks, a 58% increase over the median survival time of 24 weeks for patients treated with standard of care therapy. In this study, 25% of 28 recurrent patients survived for more than a year post-treatment and 10% of patients survived for more than three years. These data are considered a promising development in this deadly disease. Cotara has been granted orphan drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representa
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
2. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
3. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
4. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
5. NPS Pharmaceuticals to Report 2007 Financial Results
6. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
8. Notice of Bradmer Pharmaceuticals Conference Call
9. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
11. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... published today in The Lancet Neurology ... the long term neurological problems that repeated concussions ... common form of sports-related traumatic brain injury (TBI), ... include dementia, amyotrophic lateral sclerosis, and other neurological ... perhaps more concerning, is that even when the ...
(Date:7/13/2014)... research in Nature Genetics identifies a ... that causes eosinophillic esophagitis (EoE), opening up potential ... food allergy. , EoE is a chronic ... triggered by allergic hypersensitivity to certain foods and ... cells called eosinophils (part of the body,s immune ...
(Date:7/13/2014)... 13, 2014 The North American water storage ... 2013 to $5,450 million by 2018, at a CAGR of ... is expanding at a rapid pace in North America. The ... laws on water & wastewater storage and collection, and the ... market is expanding at a healthy rate in Canada, and ...
(Date:7/13/2014)... According to a new market ... by Component (processor, GPU, DSP, connectivity), Technology Node ... Geography - Forecast and Analysis to 2014-2020", published ... Computing Market is expected to reach $61.70 Billion ... from 2014 to 2020. , Browse 71 market ...
(Date:7/13/2014)... July 13, 2014 Athletes with a ... period from concussions, according to research presented today at ... ) Annual Meeting. The research marks the first of ... on the known physical events that occur after a ... a long allele in the (GT)n genotype were four ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... March Issue of Nicotine and Tobacco Research Analyzes Trends, ... date, the majority of research conducted about tobacco use ... heavy smoking. The March 2009 issue of ... light and intermittent smoking. Several of the nation,s preeminent ...
... Dr. Matt Regulski --FORT WORTH, Texas, March 20 ... Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM), ... 09 on March 19-21, 2009 at the Renaissance ... considered the premier international multidisciplinary diabetic foot conference ...
... DICK GEPHARDT SERVES ON MMR INFORMATION SYSTEMS, ... MMR Information Systems, Inc. (OTC Bulletin ... subsidiary, MyMedicalRecords, Inc. (collectively, "MMR") provides consumer-controlled ... and electronic safe deposit box storage solutions ...
... well, study says there,s no rush to abandon standard care ... of maggots to treat leg ulcers is similar to standard ... to British researchers. , Debridement (removal of dead tissue ... common part of treatment for leg ulcers, chronic wounds most ...
... SOUTH EASTON, Mass., March 20 Pressure BioSciences, Inc. ... today provided an update on various corporate activities, including ... Innovation Research ("SBIR") Grant from the National Institutes of ... of the Harvard School of Public Health ...
... Nasdaq: SHPGY ), the global specialty biopharmaceutical ... (39) lots of the ADHD patch DAYTRANA (the lots ... below). Shire is taking this action because some ... specification, and as a result, patients and caregivers could ...
Cached Medicine News:Health News:New Analysis: Light and Intermittent Smokers Overlooked in Traditional Tobacco Research 2Health News:New Analysis: Light and Intermittent Smokers Overlooked in Traditional Tobacco Research 3Health News:New Analysis: Light and Intermittent Smokers Overlooked in Traditional Tobacco Research 4Health News:Wound Management Technologies Exhibits at Premier International Diabetic Foot Conference DFCon 09 2Health News:Wound Management Technologies Exhibits at Premier International Diabetic Foot Conference DFCon 09 3Health News:Former House Democratic Leader Richard A. Gephardt to Join MMR Initiative to Promote Immediate Use of Personal Health Records 2Health News:Former House Democratic Leader Richard A. Gephardt to Join MMR Initiative to Promote Immediate Use of Personal Health Records 3Health News:Former House Democratic Leader Richard A. Gephardt to Join MMR Initiative to Promote Immediate Use of Personal Health Records 4Health News:Maggots as Good as Gel in Leg Ulcer Treatments 2Health News:Pressure BioSciences, Inc. Provides Corporate Update 2Health News:Pressure BioSciences, Inc. Provides Corporate Update 3Health News:Pressure BioSciences, Inc. Provides Corporate Update 4Health News:Pressure BioSciences, Inc. Provides Corporate Update 5Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 2Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 3Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 4Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 5
(Date:7/10/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... June 30, 2014 results on Thursday, July 31, 2014, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/10/2014)... Quebec , July 10, 2014  Valeant Pharmaceuticals ... VRX) today announced it has completed the sale to ... and Dysport owned or held by Valeant for $1.4 ... with Nestle S.A, which recently completed its acquisition of ... the divestiture of our products to a company that ...
(Date:7/10/2014)... CAESAREA, Israel , July 10, 2014 /PRNewswire/ ... Dario™ Diabetes Management Solution, today announced the appointment ... an independent member of its Board of Directors. ... of legal and business experience to LabStyle as ... director, and legal and corporate governance expert. He ...
Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... Dec. 11 As Warner Chilcott plc (Nasdaq: ... global branded prescription pharmaceuticals business of The Procter & ... Acquisition"), constituted a change of control under a global ... P&G subsidiary acquired by Warner Chilcott and Sanofi-Aventis U.S. ...
... , IRVINE, Calif., Dec. 11 PRO-DEX, INC. (Nasdaq: ... Annual Shareholders Meeting held on December 4, 2009. At the ... Healey, David Holder and Mark Murphy as directors; (ii) approved the ... split if it should elect to do so at any time ...
Cached Medicine Technology:Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes 2Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes 3Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes 4Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4
Inquire...
Inquire...
... The Micro MB for Microhematocrit meets or ... the NCCLS "Standard Procedure for the Determination ... Method" as well as other U.S. and ... Microhematocrit determinations, order Cat. No. 3411 or ...
... two centrifuges -- the world's most popular ... in one reliable, quiet, compact unit. It ... two separate centrifuges!, For your microcentrifuge needs, ... supplies you with the MicroMB centrifuge, microcentrifuge ...
Medicine Products: